University College Cork
|As first author||0|
|As last author||2|
Paul D. Cotter(7)
R Paul Ross(4)
Eamonn M M Quigley(3)
Eileen F. Murphy(3)
Gerald F Fitzgerald(3)
A. A. Hennessy(3)
Siobhan F. Clarke(3)
Paul W O’ Toole(3)
Douwe van Sinderen(2)
C Anthony Ryan(1)
... and 45 others
These arethe4 unique sources for Paul Ross's 29 publications. A single publication may appear in multiple sources. Click on a name or publication count to see the publications for a particular source.
|Ireland -> Teagasc||19|
|Ireland -> Teagasc -> PubMed||17|
|Ireland -> University College Cork||11|
|Ireland -> University College Cork -> PubMed||7|
An isolated Lactobacillus mucosae (DPC6426) strain deposited with the National Collection of Industrial and Marine Bacteria Limited (NCIMB) on 27th July 2012 under NCIMB Deposit Accession No. 42015.
Isolated bacteria are described that are characterised by being culturable, derived from a human neonatal gastrointestinal tract, and having the ability to produce gamma-aminobutyric acid. Also described is the use of the GABA-producing bacteria in the treatment or regulation of cardiovascular function, mood disturbance, anxiety, stress, pain and proliferative disorders.
An isolated bacteriophage MR299-2 or NH-4 deposited under NCIMB Deposit Accession Nos. 41729 and 41730, respectively, is described. The phages have lytic activity against P. aeruginosa strains, including mucoid and CF clinical isolate strains. Variant hages are also described, wherein said variants retain the phenotypic characteristics of said phage and wherein said phage and variants thereof have lytic activity against P. aeruginosa strains.
The invention relates to a gene derivable from the LIPI-3 pathogenicity island of the gram positive pathogen Listeria monocytogenes and to the Listeria monocytogenes cytotoxin, Listeriolysin S. The present invention further relates to the application of Listeriolysin S as a target for diagnostic screening and as a therapeutic agent such as an anti-cancer agent.
The current invention provides use of a CLA -producing bacterium for the in viv o conversion in the gut of polyunsaturated fatty acids to CLA. The CLA- producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria.
The present invention provides a plasmid pSOFLysK contained in the bacterial strain Lactococcus lactis NZ9800 referred herein as Lactococcus lactis NZ9800-pSOFLysK (subsequently designated Lactococcus lactis DPC6132) encoding anti-staphylococcal activity as deposited with DSMZ under accession No. ncimb 41409 and plasmids substantially similar thereto also providing anti-staphylococcal activity. In another aspect, the present invention provides a gene encoding an anti-staphylococcal protein, Lysin (LysK) as encoded by the plasmid pSOFLysK in Lactococcus lactis /VZ9800- pSOFLysK (subsequently designated Lactococcus lactis DPC6132). The recombinant lysine also has applications in diagnostics given its lytic mechanism.
The present invention relates to Angiotensin-I-converting enzyme inhibitors and to methods of producing such inhibitors comprising culturing a Lactobacillus strain in the presence of milk proteins. Strains useful in the production of these inhibitors are disclosed. The invention also relates to functional foods comprising such inhibitors.
The present invention relates generally to the field of health promoting agents, in particular antimicrobial agents and provides antimicrobial peptides and bacterial strains that provide the antimicrobial peptides. In one aspect, the invention provides a biologically pure culture of Lactobacillus acidophilus , strain DPC6026, a sample of which has been deposited at the National Collection of Industrial and Marine Bacteria, Aberdeen, Scotland on 18th November 2005 under the accession number NCIMB 41354, or a derivative or mutant thereof capable of producing from milk or a milk product, peptides having antimicrobial activity.
The invention provides a probiotic composition to alleviate Salmonella infection in farm animals. The composition may comprise at least one of Lactobacillus murinus, Lactobacillus pentosus, Lactobacillus salivarius sub-species salivarius, and Pediococcus pentosaceus. The composition maybe formulated as an animal feedstuff, or as a pharmaceutical composition.
Clicking through these tabs will give you a wealth of further insights into this expert through their commonly used topics, the evolution of their expertise, their collaborators and their publications.
Here is a quick breakdown of this expert's publication history
If this is the expert you have been looking for, simply click here to make contact.